Abstract: The invention relates to a mobile crane with a two-part jib and to a method for aligning the boom system of such a mobile crane. The invention relates to a mobile crane with a multi-part flight boom, wherein a first jib part is hinged to the main boom in a rockable manner, and at least one second jib part is secured to the first jib part in an articulated manner. A bracing which is guided from the upper chassis to the jib is provided for aligning the jib, said bracing running over at least one intermediate bracing support mounted on the first jib part to the at least one second jib part.

Abstract: The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (with the proviso that at least one of X1 and X2 is N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Abstract: A method for operating a ship propulsion system. A setpoint rotational speed is determined for a propeller shaft and a setpoint pitch angle for an adjustable propeller on a control side based on an adjustable propeller characteristic diagram and an operator. An engine is determined based on a ship's engine characteristic diagram and the setpoint rotational speed for the propeller shaft. An actual engine operating point is determined as a function of a measured actual rotational speed and a measured actual torque, so that when the drive power is constant, the set-point rotational speed for the propeller shaft and the pitch angle for the adjustable propeller can be varied while reducing fuel consumption of the ship's engine and, when this is possible, the setpoint rotational speed for the propeller shaft, the setpoint pitch angle for the adjustable propeller and the setpoint operating point of the ship's engine are adapted.

Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Abstract: A method for determining a gas consumption of a gas-powered gas engine or a gas-powered dual-fuel engine. The engine is operated under actual operating conditions, and the actual gas consumption of the engine is acquired under the actual operating conditions. A target gas consumption of the engine to be anticipated under target operating conditions is calculated depending on the actual gas consumption and depending on discrepancies between the actual operating conditions and the target operating conditions.

Abstract: The present application provides a tool for cleaning a groove of a turbine rotor disk. The tool may include a pair of guides spaced apart from one another in a direction of a longitudinal axis of the tool, and a number of cleaning sheets positioned between the guides in the direction of the longitudinal axis of the tool. At least a portion of each guide may have a cross-sectional profile corresponding to a cross-sectional profile of the groove, and at least a portion of each cleaning sheet may have a cross-sectional profile corresponding to the cross-sectional profile of the groove. The present application further provides a method for cleaning a groove of a turbine rotor disk, and a tool system for cleaning a groove of a turbine rotor disk.

Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: A patient-supporting device is disclosed. The patient-supporting device includes a fastening assembly that fastens the patient-supporting device to a structural member, a support member configured to receive a body part of a patient, and a height adjustment assembly that adjusts a distance between the fastening assembly and the support member. The height adjustment assembly includes a locking assembly and an elongated member. The support member is attached to a first end portion of the elongated member. The locking assembly is stationary relative to the fastening assembly. The elongated member is guided in an aperture of the locking assembly in a longitudinal direction of the elongated member. A plurality of first snap-in recesses is disposed on a first side portion of the elongated member. The locking assembly includes a first locking member.

Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Abstract: The invention relates to a substrate (2) for manufacturing an organic conversion device for converting electrical energy into light energy or light energy into electrical energy, wherein the substrate comprises a) an encapsulation layer (3) on the substrate, wherein the encapsulation layer includes a first inorganic layer (7), a second inorganic layer (9) and an intermediate organic layer (8), and b) a getter reservoir (6) in contact with the organic layer of the encapsulation layer. Water molecules will therefore not only be transported along the intermediate organic layer, but will also be gathered, especially absorbed, by the getter reservoir, if the encapsulation is damaged. This can slow down a transport of water molecules along a leakage path towards an organic conversion layer of the organic conversion device and hence slow down a possible degradation of the performance of the organic conversion device, if the encapsulation layer is damaged.

Abstract: An apparatus for producing a corrosion-protected steel product, in particular a steel strip or steel sheet, is disclosed. The apparatus includes a device for plasma nitriding a steel substrate and a coating device for applying a metallic material to the steel substrate. A process for producing a corrosion-protected steel product, in particular a steel strip or steel sheet, is also disclosed, wherein a steel substrate is provided and nitrogen is diffused by plasma nitriding into the steel substrate, and wherein a metallic material is applied to the steel substrate.

Abstract: A system for project planning for an engine for determining an operating behavior of the engine to be expected under defined operating conditions of the engine includes: a plurality of sensors configured to measure respective ones of the defined operating conditions of the engine; and a knocking intensity prediction tool configured to determine the knocking intensity of the engine to be expected under the defined operating conditions of the engine.

Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.